Widely used metabolic drugs may help curb rising colorectal cancer in younger adults

March 2, 2026

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.

Chronic pain research receives major NIH grant

February 27, 2026

A five-year, $9 million National Institutes of Health National Institute of Neurological Disorders and Stroke study that began in 2022 recently received approval at the three-year mark, allowing investigators to continue their work examining the biological mechanisms of TMJ disorders. The project is part of a national consortium of five institutions conducting complementary studies across the country.

Barshop Institute to receive up to $38 million from ARPA-H, anchoring UT San Antonio as a national leader in aging and healthy longevity science

February 24, 2026

Barshop Institute to receive up to $38 million from ARPA-H, anchoring UT San Antonio as a national leader in aging and healthy longevity science

UT Health San Antonio researcher earns grant to study how the brain’s immune cells might actually contribute to Alzheimer’s

February 20, 2026

Cure Alzheimer’s Fund award aimed at better understanding microglia’s role A researcher with the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio has received a two-year, $402,500 grant award from the Cure Alzheimer’s Fund to study how microglia, the brain’s resident immune cells, paradoxically might contribute to the spread of toxic forms of tau protein in […]

Major NIH grant renewal fuels next phase of chronic pain research at UT San Antonio

February 20, 2026

A five-year, $9 million National Institutes of Health National Institute of Neurological Disorders and Stroke study that began in 2022 recently received approval at the three-year mark, allowing investigators to continue their work examining the biological mechanisms of TMJ disorders.